Study guide
13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables
NCRA Oncology Data Specialist ODS-C
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters
1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish
2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws
2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority
3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance
3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance
4 Chapter 4: Registry Organization, Staffing & Information Systems
4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning
5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement
5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)
6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality
6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)
7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics
7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data
8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer
8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors
9 Chapter 9: Casefinding & Reportability
9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"
10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators
10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More
11 Chapter 11: Class of Case, Key Dates & Case Identifiers
11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them
12 Chapter 12: Follow-Up, Vital Status & Recurrence
12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary
13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade
13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables
14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules
14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules
15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018
15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples
16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS
16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation
13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables
Key Takeaways Explain This Topic AI
Grade Clinical [3843] and Grade Pathological [3844] must never be blank; Grade Post Therapy Clin (yc) [1068], added for 2021+, and Grade Post Therapy Path (yp) [3845] are left blank when no neoadjuvant therapy was given.
When neoadjuvant therapy is followed by a resection, Grade Pathological is coded 9, and the post-treatment resection grade goes in Grade Post Therapy Path (yp).
Grade priority is the synoptic report (CAP protocol), then the final diagnosis, then a physician statement; code grade from the primary tumor only, take the higher grade of a range, and record a consult's grade if it differs.
AJCC-recommended grading systems (codes 1–5, L, M, H, S) take priority over the generic codes A–D, which are treated as unknown when assigning an AJCC stage group.
For hematopoietic and lymphoid neoplasms (9590–9993), Grade Clinical and Grade Pathological are coded 8 and the post-therapy grades are blank; cell lineage has not been collected in grade since 2018.
Last updated: September 2026
Why grade has four items
Treatment can change a tumor's grade, and AJCC stages cancers in separate time frames. For cases diagnosed in 2018 and later, the Grade Manual replaced the old single Grade item [440] and the Collaborative Stage grade-related site-specific factors with time-specific items:
Item Time frame Blank allowed?
Grade Clinical [3843] Before any treatment: surgical resection or the start of neoadjuvant therapy. TURB and endoscopic biopsies are not treatment No. Use 9 if unknown
Grade Post Therapy Clin (yc) [1068] Microscopic sampling of the primary after neoadjuvant or primary systemic/radiation therapy, before resection. Added for 2021+ diagnoses Yes. Blank when there was no neoadjuvant therapy, no post-treatment sampling, or a clinical or pathological case only
Grade Pathological [3844] Resected primary, no neoadjuvant therapy No. Use 9 when appropriate
Grade Post Therapy Path (yp) [3845] Primary resected after neoadjuvant therapy Yes. Blank when there was no neoadjuvant therapy, or neoadjuvant therapy with no resection
General rules for solid tumors
Primary tumor only. Do not code grade from a metastasis or recurrence. The rare exception is contiguous extension when primary tissue is unavailable. If the primary site is unknown, grade is 9.
Ranges: for "grade 2–3," code the higher grade.
More than one grade in the same time frame: the AJCC-recommended system has priority. Within it, code the highest grade.
In situ and invasive: code a grade given for an in situ tumor, but never code dysplasia (for example, "high-grade dysplasia") as grade. If both in situ and invasive parts exist, code only the invasive grade, even if it is unknown.
Priority of sources: the synoptic report (including the CAP protocol), then the final diagnosis , then a physician statement .
Clinical grade before neoadjuvant therapy: code Grade Clinical from information before neoadjuvant therapy, even if it is unknown.
Consults: if outside slides are reviewed and the grade differs, record the consult grade. A facility re-read with an updated report also counts as a consult.
Only one grade, time frame unclear: code it as Grade Clinical, set Grade Pathological to 9, and leave both post-therapy items blank.
When Grade Pathological uses the clinical grade
Grade Pathological can include the clinical workup grade, because pathological staging uses all information from diagnosis through resection. Use the clinical grade when:
- the clinical and pathological behavior are the same and the clinical grade is the highest;
- the clinical diagnosis was invasive but the resection showed only in situ;
- the resection documents no grade, or there is no residual cancer ;
there was no resection, but distant metastasis was microscopically confirmed during the clinical time frame.
When Grade Pathological is 9
Grade was not documented, and no clinical grade is available.
There was no resection of the primary, except the metastasis case above.
Neoadjuvant therapy was followed by resection. The resection grade goes to yp .
It is a clinical case only, or "not applicable" was checked on the CAP protocol with no other grade.
Preferred system mismatch: the Grade Manual example is a biopsy showing a moderately differentiated adenocarcinoma, coded G2 in a table whose preferred system is differentiation, and a resection that says only "high grade," a term that table does not accept. Grade Clinical is 2 and Grade Pathological is 9 ; the clinical G2 is not copied into the pathological item.
Code structure
Codes Meaning
1–5, L, M, H, S AJCC-recommended, site-specific categories. L/M/H are for low, intermediate and high grade where AJCC uses them (for example, breast in situ nuclear grade and urothelial low/high grade). S is sarcomatous overgrowth in uterine adenosarcoma
- A–D Generic grades: A well, B moderately, C poorly differentiated, D undifferentiated or anaplastic
- E Site-specific category (for example, prostate "Gleason score 7" with no patterns)
- 8 Not applicable: hematopoietic neoplasms only
- 9 Grade cannot be assessed; unknown
- Blank Post-therapy items only
When AJCC needs grade for a stage group, codes A–D count as unknown grade , which can make the stage group unknown.
- High-yield site tables
- Breast (Grade ID 12)
Invasive: Nottingham (Scarff-Bloom-Richardson) combined histologic grade. Tubule formation, nuclear pleomorphism and mitotic count are each scored 1–3: a total of 3–5 = G1 , 6–7 = G2 , 8–9 = G3 . "Grade 2" with no other detail is assumed to be Nottingham grade.
If only "well/moderately/poorly differentiated" is stated for an invasive tumor, use A–D . Do not use L, M or H for invasive tumors.
In situ (DCIS): nuclear grade L, M, H . Notation such as "2/3" is nuclear grade. Do not use 1–3 for in situ tumors.
Nodes only (T0): grade from nodal tissue may be used only when no primary tumor was ever found.
Example: a biopsy shows DCIS, nuclear grade 3, and the lumpectomy shows invasive carcinoma with Nottingham score 7. Grade Clinical is H , Grade Pathological is 2 , and the behavior is /3.
Prostate (Grade ID 17)
- Code Grade Group Gleason
- 1 Grade Group 1 6 or less
- 2 Grade Group 2 3+4 = 7
- 3 Grade Group 3 4+3 = 7
- 4 Grade Group 4 8
- 5 Grade Group 5 9–10
- E "Gleason 7" with no patterns
Codes 1–5 take priority over A–E. A TURP or simple prostatectomy gives a clinical grade only.
Other examples
Endometrioid endometrial carcinoma: FIGO grade 1–3. The Grade Manual maps "low grade" to FIGO 2 and "high grade" to FIGO 3.
Urothelial (bladder): L (low grade) and H (high grade).
Many GI and head and neck sites: G1–G4 (well to undifferentiated).
Hematopoietic and lymphoid neoplasms
For histologies 9590–9993 , Grade Clinical and Grade Pathological are coded 8 (not applicable), and the post-therapy items are blank . The old cell-lineage indicator (B-cell, T-cell, null, NK) that used to go in Grade is no longer collected for 2018 and later cases. The exception is lymphoma of the ocular adnexa: follicular lymphoma histologies (9690, 9691, 9695, 9698) at C441, C690, C695 and C696 are graded under the AJCC ocular adnexa system.
Derived Summary Grade 2018 [1975]
Central registries derive this item from Grade Clinical and Grade Pathological, not the post-therapy items, to compare grade with pre-2018 data. Hospital registrars do not code it.
Loading diagram... Which grade item?